Clinical Trials

52 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05336721 2025-03-24

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

9 enrolled

Triple Negative Breast Neoplasms

NCT03872388 2024-10-02

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

6 enrolled 8 charts

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03387085 2024-08-09

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

9 enrolled 18 charts

Triple Negative Breast Neoplasms

NCT05163223 2024-06-17

Cornerstone001

10 enrolled

Breast Neoplasms

NCT05134194 2024-04-16

A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer

1 enrolled

Triple Negative Breast Neoplasms

NCT03322215 2024-03-08

PASIPHAE

42 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Breast Cancer Metastatic

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01873833 2023-10-05

Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer

10 enrolled 16 charts

Breast Neoplasms

NCT00665457 2023-09-13

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

3 enrolled 6 charts

Breast Neoplasms

NCT02229149 2022-12-02

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

33 enrolled

Breast Neoplasms

NCT05091528 2022-08-18

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

BreastGastrointestinalThoracic

2 enrolled 9 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

NCT00508274 2021-09-21

Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China

52 enrolled 12 charts

Breast Neoplasms

NCT04031885 2021-08-24

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Phase 4 Terminated

4 enrolled 9 charts

Breast Neoplasms

NCT03326674 2021-07-30

CONTESSA

685 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT03858972 2021-07-30

CONTESSA 2

152 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT01702558 2021-01-22

TRAXHER2

182 enrolled 44 charts

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT04274933 2020-10-29

A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

Phase 1 Terminated

4 enrolled

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00437294 2020-08-10

Enzastaurin in Combination of Capecitabine to Treat Breast Cancer

86 enrolled 20 charts

Breast Neoplasms

NCT02294786 2019-07-15

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

62 enrolled 25 charts

Breast Neoplasms, Diarrhea, Neoplasms

NCT00462865 2019-04-09

Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse

18 enrolled 8 charts

Breast Neoplasms

NCT00130507 2019-02-26

Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab

14 enrolled

Breast Neoplasms

NCT00434941 2019-02-21

Capecitabine Plus Radiotherapy for Local Relapse Breast Cancer With Negative Her2 Tumours

1 enrolled

Breast Neoplasms

NCT02297230 2018-10-15

Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics

44 enrolled 6 charts

Breast Neoplasms

NCT03358004 2018-10-05

VICTOR3

4 enrolled

Triple Negative Breast Neoplasms

NCT01887288 2018-02-22

Capecitabine With Digoxin for Metastatic Breast Cancer

16 enrolled 1 chart

Breast Neoplasms

NCT02120417 2018-02-13

A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer

149 enrolled 14 charts

Breast Neoplasms

NCT01655992 2018-01-23

A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC)

386 enrolled

Breast Neoplasms

NCT00684216 2017-09-14

Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer

Phase 2/3 Terminated

10 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT00194792 2017-07-11

Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer

28 enrolled 9 charts

Breast Neoplasms

NCT00496366 2017-03-21

Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer

11 enrolled 8 charts

Breast Neoplasms

NCT00087620 2017-02-03

A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer

Phase 4 Terminated

Breast Neoplasms

NCT02213744 2017-01-06

HERMIONE

Phase 2/3 Terminated

113 enrolled

Breast Neoplasms

NCT00977379 2016-11-15

XERAD

24 enrolled 20 charts

Breast Neoplasms

NCT00845910 2016-11-02

A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer

22 enrolled

Breast Neoplasms

NCT01132664 2016-08-17

Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer

72 enrolled 15 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT01069796 2016-03-17

Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

64 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT00546364 2016-03-10

IXTEND

62 enrolled 14 charts

Breast Neoplasms

NCT00634088 2016-03-10

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Phase 1 Terminated

13 enrolled 13 charts

Breast Neoplasms

NCT00305643 2015-12-24

Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer